Background {#Sec1}
==========

Cardiovascular disease (CVD) accounts for about one-third of all deaths in the U.S. and is the leading cause of mortality \[[@CR1]\]. Rural populations face CVD-related health disparities compared to their urban counterparts; they are less likely to meet physical activity recommendations and more likely to smoke, be overweight, and have type 2 diabetes \[[@CR2], [@CR3]\]. Rural women face additional health risk factors in terms of income, education, age, and insurance \[[@CR2]\]. Environmental aspects of rural areas, including limited access to physical activity opportunities, healthy foods, and healthcare resources, contribute to development of these risk factors \[[@CR4]--[@CR6]\]. Therefore, women in rural, medically underserved areas are a critical population for CVD prevention interventions.

Health policy makers face difficult choices between funding targeted CVD prevention efforts, other public health efforts, and clinical healthcare. Economic evaluation methods are used to guide scarce societal resources to their highly valued use in improving health \[[@CR7], [@CR8]\]. Investments in prevention can be particularly attractive when they reduce the need for future clinical healthcare spending \[[@CR9]\]. More often, prevention adds to healthcare costs, but can still provide an attractive return on investment compared to other options to improve health \[[@CR10]\].

Community-based CVD, type 2 diabetes, and obesity prevention programs are generally found to be cost-effective \[[@CR11]--[@CR13]\] Because midlife and older rural women face health disparities and rural areas may lack healthy lifestyle resources, CVD prevention programs are critical for this population. Relatively few cost-effectiveness analyses (CEAs) have been performed for community-based healthy lifestyle interventions in rural areas \[[@CR14]--[@CR18]\]. Some of these previous studies were not randomized controlled trials \[[@CR14], [@CR18]\], combined results from urban and rural areas \[[@CR14]\], had under 50 participants \[[@CR17], [@CR18]\] or did not report the number of participants \[[@CR14]\], included men and women \[[@CR14], [@CR15], [@CR18]\], and/or included young adults, as well as midlife and older adults \[[@CR15], [@CR17]\]. Only one previous CEA has been done on a community-based healthy lifestyle behavior change program studying only midlife and older rural women, in the United States, with over 50 participants \[[@CR16]\].

In this paper, we report the results of economic evaluations of a rural community-based CVD prevention program targeted at overweight and obese rural women aged 40 and older. Strong Hearts, Healthy Communities (SHHC) was an innovative community-based six-month intervention informed by the socioecological framework to target key behaviors related to CVD prevention and overweight/obesity. We hypothesized that the cost-effectiveness of SHHC would compare favorably with other interventions and commonly used thresholds for acceptable costs per quality-adjusted life year (QALY) saved.

Methods {#Sec2}
=======

Research design {#Sec3}
---------------

We conducted economic evaluations of SHHC alongside a two-armed randomized controlled efficacy trial. The economic evaluations include a program cost analysis (CA) and CEAs that adopted alternative perspectives and used multiple health outcome measures. The study protocol for the efficacy trial has been previously published \[[@CR19]\]. The study was approved by the Cornell University and Bassett Healthcare Institutional Review Boards.

The efficacy trial compared the multilevel SHHC intervention to a minimal, education-only control program, Strong Hearts, Healthy Women (CON). Randomization occurred at the town level, with half randomized to deliver the SHHC intervention program and half to deliver the CON program. The primary outcomes of the efficacy trial were kg of body weight and BMI; physiological measures and two composite measures of cardiovascular disease risk were also evaluated \[[@CR20]\].

Participants and setting {#Sec4}
------------------------

Sedentary overweight or obese women aged 40 and older were recruited from 16 medically underserved rural towns in Montana and New York. Participants were recruited by local health educators. Eligible participants were female, 40 years or older, overweight (BMI \> 25), sedentary, English-speaking, and had their physician's approval to participate. Participants with blood pressure \> 160 (systolic) or \> 100 (diastolic), heart rates of \< 60 or \> 100, or cognitive impairments were excluded. All participants provided written informed consent. A total of 436 participants were assessed for eligibility; 194 participants enrolled.

Interventions {#Sec5}
-------------

Based on previous effective programs \[[@CR21]--[@CR23]\], the SHHC multilevel CVD prevention program targeted individual (experiential learning around dietary intake and physical activity, including aerobic exercise and strength training), social (activities including family and friends), and community (civic engagement curriculum designed to catalyze positive built environment) levels. SHHC classes met for 1 hour twice weekly for 24 weeks (48 classes total).

The Strong Hearts, Healthy Women control (CON) classes served as the reduced-dose, education-only, minimal intervention control program. Classes provided evidence-based healthy lifestyle information (e.g. current dietary and physical activity guidelines) presented didactically. Participants did not engage in physical activity, skill building, or other active learning elements (e.g. reflection, monitoring) or civic engagement during the class sessions. The CON classes met for a one-hour class once per month over 24 weeks (six classes total).

Perspectives of the CEA {#Sec6}
-----------------------

The CA and one set of CEAs were conducted from the payer perspective, which means we estimated how much the intervention's payer or sponsor paid for the intervention. When we adopted the payer perspective, we focused on costs directly incurred to administer and implement the program. The results of the payer perspective analysis provide crucial information for local health policy makers to judge whether and under what circumstances SHHC should be disseminated.

As recommended by the Second Panel on Cost-Effectiveness in Health and Medicine \[[@CR7]\], we also conducted Reference Case CEAs from two broader perspectives. The Reference Case CEAs from the broad societal perspective consider all significant health outcomes and costs, including participants' direct and opportunity costs, that flow from the intervention. The Reference Case CEAs from the healthcare sector perspective consider formal healthcare sector (medical) costs borne by third-party payors or paid out-of-pocket by patients. The results of the Reference Case analyses allows comparison of the cost-effectiveness of SHHC to existing cost-effectiveness research on a broad range of prevention and clinical interventions.

Health outcomes {#Sec7}
---------------

In one set of CEAs, we used the health outcomes measured in the efficacy trial. In these CEAs we examined the cost per kg of body weight reduction; the cost per point of BMI reduction; the cost per mg/L of C-reactive protein (CRP) reduction; and the cost per point of Simple 7 increase. Simple 7 is a composite cardiovascular health metric composed of four health behaviors (non-smoking, appropriate BMI, physical activity, healthy diet) and three health factors (total cholesterol, blood pressure, fasting glucose) \[[@CR24]\].

In another CEA we used the ten-year risk for atherosclerotic cardiovascular disease (ASCVD) to conduct CEA in terms of cost per QALY saved. ASCVD risk was calculated using the Pooled Cohort Equations based on age, total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure (including treated or untreated status), diabetes, and current smoking status \[[@CR25]\]. We used previously published estimates to calculate the QALYs saved per ASCVD event prevented \[[@CR26]\].

Costs {#Sec8}
-----

For the CA and the CEAs from the payer perspective, we identified the resources directly used in program administration and implementation and collected measures of the associated tangible costs. The categories of resource use were labor, facilities (space and utilities), food, equipment, curriculum printing, and other. Labor resources include staff training and preparation time, as well as staff time to deliver the interventions. Information on resource use was provided as administrative records or collected via surveys of the program administrators. Administrative records on staff compensation including salary and fringe benefits were used to calculate labor costs. Administrative records also provided the information on the costs of food, equipment, and curriculum printing. The labor and food costs are provided at the site-level. The equipment and printing costs are overall estimates. The space rental fees and other costs are estimated based on a dataset from a survey of agents and coordinators. Site level costs are taken from administrative records (labor, food, equipment, and printing) or estimated as site level means from surveys (rent, other costs, and participants' gasoline and time). Missing site level costs for labor, rent, and others are replaced by the mean cost per site within the SHHC or CON program. Missing food and participant costs are estimated based on the mean cost per enrollee per site within program. The total costs for SHHC and CON are the sum of all their sites' costs.

For the Reference Case CEAs from the societal perspective, we measured not only the direct program resource costs, but also the opportunity cost of all resources used as a result of the intervention. Costs to participants are an important component of the opportunity costs included from the societal perspective. Participants give up time that could have been used in other valued ways such as labor market work, household work, or leisure activities. We collected information on participant costs from surveys of participants. We followed standard practice and measured the value of participants' time based on the relevant wage rates.

For the Reference Case CEAs from the healthcare sector perspective, we used estimates of the medical costs of CVD events \[[@CR27]\]. The estimates are from a study that used administrative claims data from a large U.S. health plan to predict medical costs of coronary heart disease and stroke events.

Analyses {#Sec9}
--------

The CA calculated the total and per participant costs of the resources used in the administration and implementation of the SHHC and CON interventions. The CEAs calculate incremental cost-effectiveness ratios (ICERs) as the ratio of the incremental costs over the incremental effectiveness.

In the intermediate health outcomes CEAs, the incremental costs were calculated as the per participant costs in the SHHC intervention minus the per participant costs in the CON. The incremental effectiveness estimates were taken from the between group multivariate analysis of the SHHC intervention's impact compared to the CON on weight, BMI, CRP, and Simple 7 score \[[@CR20]\].

In the QALY CEA, the incremental costs and effectiveness compare the SHHC intervention to the status quo alternative (no intervention). We conducted the analysis for a hypothetical cohort of 2.2 million women. The cohort size corresponds to a hypothetical nationwide SHHC intervention that reaches all midlife and older overweight and obese women in rural medically underserved communities \[[@CR28]\]. We used the incidence rates for 55--64 year-old women to predict the status quo number of CVD events in a cohort this size over a 10-year time horizon. We predicted the number of CVD events after the hypothetical SHHC intervention based on the pre-post within group multivariate analysis of the SHHC's intervention impact on ASCVD risk (Table [2](#Tab2){ref-type="table"} in \[[@CR20]\]). We use the pre-post within group analysis because the estimated  between-group change for ASCVD risk (Table [3](#Tab3){ref-type="table"} in \[[@CR20]\]) has a wider confidence interval possibly due to a relatively small sample size, less suitable controls, or other factors. For each CVD event, we calculated the associated QALYs and healthcare costs based on previously published estimates \[[@CR26], [@CR27]\]. The QALY losses from CVD events were calculated relative to the expected QALYs in a population of older obese women.

We conducted probabilistic sensitivity analysis to characterize parameter uncertainty in the CEAs. The analysis treats each parameter as a random variable with an assumed mean, range, and probability distribution. We conducted Monte Carlo simulations with a sample of 1000 observations, each observation representing a hypothetical trial. The simulation results are 1000 observations of incremental costs, effects, and ICERs. We graphically present the results on cost-effectiveness planes.

For the QALY CEA, we use cost-effectiveness acceptability curves to present the probability that the SHHC intervention is acceptable for a range of willingness-to-pay thresholds. The range of willingness-to-pay thresholds for QALYs includes consensus estimates of societal willingness-to-pay per QALY saved Analyses were conducted using Stata 15 (StataCorp. 2017. *Stata Statistical Software: Release 15*. College Station, TX: StataCorp LLC).

Results {#Sec10}
=======

Program cost analysis {#Sec11}
---------------------

The total costs of the direct resources used in the administration and implementation of the SHHC intervention were \$78,229 (Table [1](#Tab1){ref-type="table"}, all costs are in 2016 US dollars).Table 1Program resource costs from the payer perspective, \$SHHCCONCost category Labor35,2388563 Space2291286 Food7182995 Equipment27,7810 Printing1336195 Other44000Total cost78,22910,040 Number of participants10193Total cost per person775108

The resource cost per participant was \$775. The total costs of the minimal intervention education-only CON were \$10,040 and the cost per participant was \$108. From the societal perspective that includes participants' direct and opportunity costs, the cost per SHHC participant increases to \$1087 and the cost per CON participant increases to \$201 (Table [2](#Tab2){ref-type="table"}). The largest cost component is the opportunity cost of participants' time. The Second Panel on Cost-Effectiveness in Health and Medicine \[[@CR7]\] recommends including the opportunity costs of time, but a previous CEA of a similar intervention was not able to take them into account \[[@CR16], [@CR29], [@CR30]\]. These results in Table [2](#Tab2){ref-type="table"} highlight the importance of the opportunity cost when evaluating participant-time intensive interventions.Table 2Participants' direct and opportunity costs, \$ per personSHHCCONCost category Gasoline for travel in personal auto3017 Time costs1058183Total participant cost1087201

Intermediate health outcomes CEAs {#Sec12}
---------------------------------

The calculated ICERs from the payer perspective show that the SHHC intervention costs \$360 per kg of weight loss, \$939 per unit of BMI reduction, \$580 per mg/L CRP reduction, and \$995 per unit increase in Simple 7 (Table [3](#Tab3){ref-type="table"}). The ICERs from the societal perspective are \$840 per kg of weight loss, \$2187 per unit of BMI reduction, \$1351 per mg/L CRP reduction, and \$2318 per unit increase in Simple 7.Table 3Cost-effectiveness of SHHC for intermediate health outcomesIncremental betweenICER from the perspective ofSHHC--CONPayerSocietyCosts, \$ per participant Resource667√√ Participant887√Total1553Outcomes, per participant Weight loss, kg−1.85360840 BMI reduction−0.719392187 CRP reduction, mg/L−1.155801351 Simple 7 increase0.679952318The "√" indicates incremental costs used in the ICER calculation under alternative perspectives

The variables examined in the probabilistic sensitivity analysis are presented in Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}. The probabilistic sensitivity analysis show that there is considerable uncertainty in the estimated ICERs for the intermediate health outcomes (Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"} and [4](#Fig4){ref-type="fig"}). The width (on the X axis) of the scatter plots of points in Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"} and [4](#Fig4){ref-type="fig"} reflects uncertainty about the SHHC intervention's effectiveness (incremental changes in the outcomes), based on the 95% confidence intervals of the estimates from the between group multivariate analysis in the efficacy trial \[[@CR20]\]. The height (on the Y axis) of the scatter plots of points reflects uncertainty about SHHC costs (incremental changes in costs from the societal perspective). To illustrate the degree of uncertainty in the resulting ICERs for weight loss, the 5 and 95% ICERs are \$548 and \$1805 per kg of weight loss. Note that in Table [5](#Tab5){ref-type="table"}, the incidence rates for CHD and stroke are not the assumed CHD or stroke rates for the hypothetical population in the probabilistic sensitivity analysis. The ratio of the two incidence rates is used in the probabilistic sensitivity analysis to partition the reduction of an ASCVD event into a CHD event reduction and a stroke event reduction.Table 4Parameters and variables examined in the probabilistic sensitivity analysis. Parameters with fixed valuesParameterValueN (trials)1000Discount rate0.03Incidence rate, 55--64 Females CHD0.003 Stroke0.002Table 5Parameters and variables examined in the probabilistic sensitivity analysis. Parameters with varied valuesParameterDistributionMeanRangeOutcomes BMI reductionNormal0.710.08--1.35(95% CI of mean) Weight lossNormal1.850.16--3.55(95% CI of mean) CRP reduction, mg/LNormal1.150.15--2.16(95% CI of mean) Simple 7 increaseNormal0.670.14--1.21(95% CI of mean) Annual ASCVD risk reductionLog normal0.000960.00043--0.00149(95% CI of mean)Costs, per person Resources of SHHCΥ, gamma775581--968(±25% of mean) Resources of SHHC-CONΥ, gamma667500--833(±25% of mean) Participant of SHHCΥ, gamma1087815--1359(±25% of mean) Participant of SHHC-CONΥ, gamma887665--1108(±25% of mean)Medical cost, 2013 \$ CHD (nonfatal mi)Υ, gamma62,20052,870--71,530(±15% of mean) Stroke (nonfatal)Υ, gamma20,50917,433--23,585(±15% of mean) Follow-up visit, 2013 \$Υ, gamma7553--98(±30% of mean)QALYs Women age 55--64, BMI 30--40β, beta0.7980.678--0.918(±15% of mean) CHDβ, beta0.6970.592--0.802(±15% of mean) Strokeβ, beta0.5900.502--0.679(±15% of mean)The incidence rates are not the assumed CHD or stroke rates for the hypothetical population in the probabilistic sensitivity analysis. The ratio of the two incidence rates is used in the probabilistic sensitivity analysis to partition the reduction of an ASCVD event into a CHD event reduction and a stroke event reductionFig. 1Sensitivity analysis of SHHC's cost and effectiveness on weight lossFig. 2Sensitivity analysis of SHHC's cost and effectiveness on BMI reductionFig. 3Sensitivity analysis of SHHC's cost and effectiveness on CRP reductionFig. 4Sensitivity analysis of SHHC's cost and effectiveness on Simple 7 increase

QALY CEA {#Sec13}
--------

From the societal perspective, which reflects all costs of the intervention to society over a 10-year time horizon, a hypothetical national SHHC is estimated to cost \$238,271 per QALY gained (Table [6](#Tab6){ref-type="table"}). From the healthcare sector perspective, the national SHHC is estimated to cost \$62,646 per QALY.Table 6Costs and effectiveness over the next 10 years of SHHC for a national sampleSHHCStatus QuoIncremental ofICERs from perspective ofSHHC−Status Quo*HealthcareSociety*Costs, \$ Resource1,716,954,54901,716,954,549√√ Healthcare3,608,071,9714,465,435,607−857,363,637√√ Participant2,409,841,51602,409,841,516√ Total7,734,868,0364,465,435,6073,269,432,429Health effects Heart events53,73466,502−12,768 Stroke events35,82344,335−8512 QALYs saved15,031,83315,018,11213,72162,646238,271"√" indicates incremental costs used in ICER calculation under alternative perspectives. The heart events and stroke events are non-fatal events

The hypothetical national SHHC is estimated to prevent 12,768 heart events and 8512 stroke events (both non-fatal events) (Table [6](#Tab6){ref-type="table"}). By preventing these events, SHHC is estimated to reduce healthcare sector costs by \$857 million, which is the healthcare cost savings that would have been spent to treat the heart and stroke events in absence of the national SHHC. However, these healthcare cost savings are not sufficient to offset the resource and participant costs (about \$4127 million) of the national intervention to a hypothetical cohort of 2.2 million women.

The probabilistic sensitivity analysis shows that there is again considerable uncertainty in the estimated societal cost per QALY gained. The results are summarized in a CEA acceptability curve, which shows the probabilities the national SHHC intervention is cost-effective at different thresholds for societal willingness-to-pay per QALY (Fig. [5](#Fig5){ref-type="fig"}). The probabilities of cost-effectiveness are measured as the fraction of estimated ICERs in the sensitivity analysis that are below each threshold.Fig. 5Cost-effectiveness acceptability curve based on a sensitivity analysis of SHHC's cost and ASCVD risk reduction

There is not agreement on the appropriate willingness-to-pay threshold \[[@CR8]\], but thresholds of \$50,000 and \$100,000 per QALY are commonly considered \[[@CR29]\]. The national SHHC is very unlikely to be cost-effective at these thresholds. A recent federal guideline for regulatory impact analysis estimates willingness-to-pay per QALY based on estimates of the value of a statistical life (VSL) \[[@CR30]\]. The range of VSL estimates imply that willingness-to-pay ranges from \$230,000 to \$750,000 per QALY; the central VSL estimate implies willingness-to-pay per QALY is \$490,000. The probability the national SHHC intervention is cost-effective is 48% using the \$230,000 threshold, 93% using the central threshold of \$490,000 and almost 97% using the \$750,000 threshold.

Site-level cost-effectiveness analysis {#Sec14}
--------------------------------------

In addition to the overall CA and CEA of the SHHC program, which took place at eight SHHC sites (towns) and eight CON sites in Montana and New York, we estimated SHHC's costs and cost-effectiveness at the site level. The site level CA is the first step of the CA for the SHHC and CON interventions as a whole. The overall costs for SHHC and CON are simply the sum of the estimated costs in the eight SHHC sites and eight CON sites, respectively. Results of the site level CA are reported in [Appendix](#Sec20){ref-type="sec"} Tables 9 and 10. The primary purpose of the site level CEA is to investigate the variation of SHHC's cost-effectiveness measured by ICERs. Unlike the overall CEA for the intermediate health outcomes (BMI, etc.), which compared SHHC with the CON, the site level CEA looked at incremental changes within group for SHHC sites (compared SHHC with status quo or the post- versus pre-intervention) for all outcomes. The site level effects of SHHC are reported in [Appendix](#Sec20){ref-type="sec"} Table 11. The cost-effectiveness of SHHC in terms of ICERs is estimated from both the payer and society perspective and reported in Tables [7](#Tab7){ref-type="table"} and [8](#Tab8){ref-type="table"}, respectively.Table 7By site - Cost-effectiveness of SHHC. ICERs (vs Status Quo) from the payer or healthcare sector perspectiveSite IDWeight lossBMI reductionCRP reductionSimple 7 increaseASCVD QALY saved3284759\*93,4773495136,2765156394442675455,7796\*830\*2502482134158,9248343954921921186,004111576253411811−16,991127931920420370396,84114321829471439− 948016290741572859\*1,386,823ICERs for QALY saved are estimated from the healthcare perspective and ICERs for other outcomes are from the payer perspective. The negative ICERs represent cost savings. The "\*" implies that the effect is in the unexpected direction. For example, an ICER for weight loss with "\*" implies that on average participants gained instead of lost body weight after the SHHCTable 8By site - Cost-effectiveness of SHHC. ICERs (vs Status Quo) from the societal perspectiveSite IDWeight lossBMI reductionCRP reductionSimple 7 increaseASCVD QALY saved36831823\*224,4558392414,77054081028115317621,290,0216\*1692\*50999832732184,9058681189218271827430,353114361729945501263,4291222915547121410681,264,574147191854105598356,11816790202215602342\*3,674,482The "\*" implies that the effect is in the unexpected direction. For example, an ICER for weight loss with "\*" implies that on average participants gained instead of lost body weight after the SHHC

As in the sensitivity analysis results, the site level analysis results also show considerable variation in SHHC's costs, effects, and cost-effectiveness across sites. For example, the total resource cost per participant across SHHC sites ranges from \$575 (Site 12) up to \$1106 (Site 8) ([Appendix](#Sec20){ref-type="sec"} Table 10). The change of health outcome may be in the opposite of the expected direction for all health outcomes except the Simple 7. For example, SHHC participants from Site 6 on average gained weight (instead of lost) by 1.13 kg after the intervention and SHHC participants from Site 16 on average had a very small increase of ASCVD risk over the next 10 years by 0.07%, which results in a large ICER (3.67 million from societal perspective) for per QALY lost ([Appendix](#Sec20){ref-type="sec"} Table 11). While from the societal perspective ICERs for QALY saved are relatively high in most sites, from the healthcare perspective, they are negative, indicating cost savings in Site 11 and Site 14 (Tables [7](#Tab7){ref-type="table"} and [8](#Tab8){ref-type="table"}). In these two sites the SHHC resource cost is below the medical care cost that would be saved or prevented over the next 10 years per QALY saved.

Discussion {#Sec15}
==========

In the CA, the resource cost per SHHC participant (\$775) was somewhat higher than the costs of a few other previously studied weight loss and nutrition interventions. The average cost of providing WISEWOMAN services was \$270 per participant \[[@CR31]\]. Because data was compiled from unique WISEWOMAN programs in multiple states, it is not possible to directly compare the program to SHHC (e.g. number of classes). An economic evaluation of the Lifestyle Education for Activity and Nutrition (LEAN) Study reported average cost per participant ranging from \$54 (multi-sensor armband only) to \$365 (multi-sensor armband plus 14 group weight loss education classes) \[[@CR32]\]. The only previous CEA of a community-based healthy lifestyle program in the United States with midlife and older rural women, having over 50 participants was a 12-month extended care lifestyle maintenance program after an initial six-month weight loss program \[[@CR16]\]. Participants attended twice-monthly (24 total) face-to-face group sessions or twice-monthly (24 total) individual telephone sessions or received 24 newsletters \[[@CR16]\]. Program costs were \$420, \$268, and \$226 per participant for the face-to-face, telephone, and control programs, respectively \[[@CR16]\]. SHHC cost \$775 per participant for the 48 sessions and the 6-session control program cost \$108 per participant. Conversely, SHHC is comparable in cost per participant to an economic evaluation of the Expanded Food and Nutrition Education Program, which reported average direct (resource) costs per graduate as \$715 \[[@CR33]\]. In this program, participants attended six or more nutrition education classes, compared to 48 classes for SHHC participants.

Adding the opportunity cost of participants' time substantially increases the costs from the societal perspective. Program administrators considering adoption of SHHC do not necessarily consider these costs because they do not have a direct impact on program budgets. However, the need to consider these costs imposed on participants is well-established in the theoretical foundations of CEA. Moreover, time costs might be an important barrier to widespread participation in an intensive intervention like SHHC.

Regarding ASCVD risk reduction, the cost-effectiveness of SHHC may be compared with the WISEWOMAN program \[[@CR31], [@CR34]\]. A cost-effectiveness study of the WISEWOMAN found that the program cost \$4400 (about \$5300 in 2016 dollars) per life-year gained. Calculated in a similar way, SHHC would cost about \$8600 per life-year gained. The higher cost per life-year gained in SHHC than WISEWOMAN may be related to two factors. One is that the SHHC intervention is more intensive and therefore, more costly. The other factor is the difference in sample characteristics. Compared with the WISEWOMAN sample, SHHC participants are older (average age 59 versus 52) and are already almost a completely non-smoking group (5% versus 23% smoking). The sample difference suggests that it may be more difficult for the SHHC sample to achieve ASCVD risk improvement quickly than the WISEWOMAN sample.

By the measure of cost per QALY (or disability -adjusted life year (DALY)) saved, SHHC is less cost-effective compared with other lifestyle interventions that also help older people to lose weight \[[@CR12], [@CR13]\]. Seven such studies included in two recent review studies report cost-effectiveness ratios ranging from about 3700US\$ (4-year time frame) per QALY to 92,100--99,200US\$ (12-month time frame) per DALY from the healthcare sector perspective \[[@CR35]--[@CR39]\]. One study reported about 13,700--15,300US\$ (6-month time frame) per life-year gained from the society perspective \[[@CR40]\]; and another study reported about 51,700US\$ (12-month time frame) per QALY with an unclear study perspective \[[@CR41]\]. Besides SHHC's high intensiveness and disadvantaged target population, its high estimated cost per QALY may be related to the parameters and approach used in the estimation. Other studies often use a longer time frame. We currently estimate ASCVD risk improvement for the next 10 years. If we assume the same effect on ASCVD risk improvement would continue for another 10 years (from continued lower weight, etc.), the SHHC's cost per QALY would be about \$68,700 from the societal perspective and \$5300 from the health sector perspective.

It is unknown whether CVD prevention programs similar to SHHC cost more to implement in rural versus urban areas. Urban communities are more likely to have public recreational facilities and programs \[[@CR42]\] and may have more opportunities to form cooperative agreements and partnerships to maximize the use of facilities and staff time (e.g. with fitness centers or community organizations), reducing the overall cost of a CVD prevention program similar to SHHC.

A national SHHC intervention is likely to be cost-effective at willingness-to-pay thresholds based on guidelines for federal regulatory impact analysis. However, it is not likely to be cost-effective at commonly used lower threshold values. The cost-effectiveness of SHHC reflects a common tradeoff in the economics of prevention. Each CVD event prevented generates substantial healthcare cost savings. However, the intervention must be delivered to a large number of participants per CVD event prevented, which can be particularly difficult in medically underserved rural areas.

Strengths {#Sec16}
---------

This study is the first to evaluate the economic effectiveness of a multilevel community-based CVD prevention program for midlife and older women in rural, medically underserved areas via comprehensive CA and CEAs. Previous community-based lifestyle behavior change interventions in rural areas lacked comparison groups; had small sample sizes; and/or included younger adults, both men and women; or included telephone-based programs. Additionally, previous studies did not include participant time costs.

Limitations {#Sec17}
-----------

SHHC was a multilevel intervention, which required additional staff and participant time, and included social and community components that were not measured. Primary outcomes for SHHC were measured at six months; future CEAs should collect data that would enable measurement of the longer-term impact on individuals, as well as on social and community components targeted by SHHC.

One limitation of our study is not having converted all of the intervention benefits into QALYs, which can be used to compare with a wider range of interventions. The estimated QALYs saved in our analysis come from the reduced ASCVD risk by the SHHC program. Other benefits of the SHHC program may also save QALYs. For example, the SHHC program reduces BMI, which may prevent diabetes and save QALYs.

Our assumption that with the initial intervention cost of \$775, the intervention's benefit of ASCVD risk reduction would last for the next 10 years is not entirely reasonable due to the likelihood of weight regain or changes in other relevant factors. Additional costs may be incurred to maintain participants' healthier status and ASCVD benefit but they may also increase the total intervention cost. Not taking into account the possible future costs is a limitation of this study.

We attribute the change in ASCVD risk scores pre and post the SHHC program as the causal effect of the intervention. This approach of using the prediction model for ASCVD risk score in a causal sense has limitations. This is a general problem with chronic disease prevention: it is costly and takes decades to run randomized controlled trials with hard ASCVD events as outcomes, so it is common to use epidemiologic modelling to translate the changes in outcomes measured in the randomized controlled trials into the changes in health outcomes and QALYs.

Another limitation of our study is not using the lifetime frame for the estimation of the benefits and costs of the reduced ASCVD risk by the SHHC program. We use the 10-year frame because the ASCVD risk measure is for a 10-year period. The limited time horizon may result in under- or over-estimated cost-effectiveness of the SHHC on ASCVD risk.

The last limitation of our study is that we do not have cost information for the ASCVD events for our study population. However, our estimates of ICERs for QALY saved are not very sensitive to the medical costs. For example, the ICERs for QALYs saved decrease slightly (more from the health sector perspective than from the societal perspective) if we increase the assumed stroke event cost from \$20,509 to \$50,000.

Recommendations {#Sec18}
---------------

To improve the cost-effectiveness of SHHC, the program could be adapted to achieve greater impacts on weight, Simple 7, and ASCVD as well as to further impact additional individuals (through individual, social, or community components). The intervention could also reduce staff from one educator and one program assistant down to just one educator. Participant time or other costs, such as space rental, could also be reduced. To impact more individuals, participants could attend classes with a friend or family member.

Conclusions {#Sec19}
===========

The results of the economic evaluations of the SHHC intervention are informative for U.S. health policy. Policy makers should give a higher priority to implement other more cost-effective interventions, but the SHHC intervention still represents a reasonable return on investment. There might also be opportunities to better target the intervention to improve cost-effectiveness and it may be that programs similar to SHHC are more expensive to operate in rural areas.

Appendix {#Sec20}
========

Table 9By site - Cost by categories, \$GroupSite IDEnrolleesResource costParticipant costFoodLaborSpaceOtherEquipmentPrintingGasTimeCON1141994243600246411496CON2131567683600241452096CON7951528360024493004CON912981772360024821575CON101114818603600241912016CON13109310703600241731833CON151212510703600242082199CON171212510703600242082199SHHC3139924405501000347316738513,748SHHC51310163424150550347316738513,748SHHC612959551211500347316716511,520SHHC812121264404751500347316735512,690SHHC11138514288500347316759215,015SHHC12123062360100500347316735512,690SHHC14117814405286550347316732611,633SHHC16151066440530300347316744415,863

Table 10By site - Total costs per participant, \$GroupSite IDResourcesResources and participantCON149201CON276248CON771410CON9161299CON10188389CON13122323CON15105305CON17105305SHHC37761863SHHC56751762SHHC69381912SHHC811062193SHHC116791880SHHC125751663SHHC148781965SHHC166291716

Table 11By site - Effects of SHHC (vs Status Quo), per participantSite IDWeight, kgBMICRPSimple 7ASCVD risk,%QALYsMedical cost,\$3−2.73−1.020.010.22−0.610.0039− 2445−4.32−1.71−1.531−0.20.0013−8161.130.38−1.950.7−1.20.0077− 4838−3.22−1.16−1.21.2−0.690.0044− 27811−4.32−1.09−1.990.38−2.320.0149− 93312−0.73−0.3− 1.371.56− 0.190.0013−7814−2.73− 1.06− 1.862−2.570.0166− 103516−2.17−0.85− 1.10.730.07−0.000530Notes: Changes for ASCVD risk, QALYs saved, and Medical cost are for the next 10 years

ASCVD

:   Atherosclerotic cardiovascular disease

CA

:   Cost analysis

CEA

:   Cost-effectiveness analysis

CHD

:   Coronary heart disease

CON

:   Minimal, education-only control program

CRP

:   C-reactive protein

CVD

:   Cardiovascular disease

DALY

:   Disability-adjusted life year

ICER

:   Incremental cost-effectiveness ratio

LEAN

:   Lifestyle Education for Activity and Nutrition

QALY

:   Quality-adjusted life year

SHHC

:   Strong Hearts, Healthy Communities

VSL

:   Value of a statistical life
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